Non-progression, defined as complete response, partial response, or stable disease (osteosarcoma) At 6 months [clinicaltrials_resource:36b3d7668fb651bd1e89240d5a7ae206]
The best overall response is the best response recorded from the start of the treatment until disease progression/recurrence (taking as reference for progressive disease the smallest measurements recorded since the treatment started). Will be analyzed independently for each stratum (osteosarcoma and Ewing sarcoma). Will be described using frequency, percentage, and 95% confidence interval (binomial law).
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]
Non-progression, defined as complete response, partial response, or stable disease (osteosarcoma) At 6 months [clinicaltrials_resource:36b3d7668fb651bd1e89240d5a7ae206]
The best overall response is the best response recorded from the start of the treatment until disease progression/recurrence (taking as reference for progressive disease the smallest measurements recorded since the treatment started). Will be analyzed independently for each stratum (osteosarcoma and Ewing sarcoma). Will be described using frequency, percentage, and 95% confidence interval (binomial law).
Bio2RDF identifier
36b3d7668fb651bd1e89240d5a7ae206
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:36b3d7668fb651bd1e89240d5a7ae206
measure [clinicaltrials_vocabulary:measure]
Non-progression, defined as co ...... stable disease (osteosarcoma)
time frame [clinicaltrials_vocabulary:time-frame]
At 6 months
description
The best overall response is t ...... dence interval (binomial law).
identifier
clinicaltrials_resource:36b3d7668fb651bd1e89240d5a7ae206
title
Non-progression, defined as co ...... ase (osteosarcoma) At 6 months
@en
type
label
Non-progression, defined as co ...... 3d7668fb651bd1e89240d5a7ae206]
@en